Search
Research
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trialAboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. We compared immunogenicity (ELISA and opsonophagocytic activity) of a combination of Synflorix™ (PHiD-CV10, 10 serotypes and protein D of NTHi) and Prevenar13™ (PCV13, 10 serotypes plus 3, 6A, and 19A), with recommended schedules.
Research
Rheumatic Heart Disease Control Programs, Registers, and Access to CareThis chapter outlines the evidence and evolution of RHD control programs and draws conclusions about priorities following the 2018 World Health Organization Global Resolution on rheumatic fever and RHD.
Research
END RHD Community Project - Kimberley (Rheumatic Fever Strategy)Kimberley Aboriginal Medical Services, Nirrumbuk Environmental Health and Services and The Kids Research Institute Australia seek to implement and evaluate a community-led project, funded by the Department of Health, to prevent and manage RHD in a selected high-risk Aboriginal community
Research
Improving delivery of secondary prophylaxis for rheumatic heart diseaseContinued progress in controlling RHD requires an understanding of how to improve delivery of regular injections of penicillin - secondary prophylaxis (SP).
Research
RHD ActionRHD Action is the name given to the global movement to reduce the burden of rheumatic heart disease (RHD) in vulnerable populations of all ages throughout the world.
Research
Strep A Vaccine Global Consortium (SAVAC) 2.0The mission of SAVAC, the Strep A Vaccine Global Consortium, to ensure that safe, effective and affordable Strep A vaccines are available and implemented to decrease the burden of Strep A disease in the most in need.
Research
Diverse diagnostic and management approaches for acute rheumatic fever in Australia and New Zealand: findings of a prospective clinical studyThis study provides new knowledge on ARF characteristics and management and highlights international variation in diagnostic and management practice.
Research
Lessons learned in the development of sustained release penicillin drug delivery systems for the prophylactic treatment of rheumatic heart disease (RHD)The current prophylactic treatment to prevent rheumatic heart disease requires four-weekly intramuscular injection of a suspension of the poorly soluble benzathine salt form of penicillin G (BPG) often for more than 10 years. In seeking to reduce the frequency of administration to improve adherence, biodegradable polymer matrices have been investigated.
Research
Calculation of the age of the first infection for skin sores and scabies in five remote communities in northern AustraliaPrevalence of skin sores and scabies in remote Australian Aboriginal communities remains unacceptably high, with Group A Streptococcus (GAS) the dominant pathogen. We aim to better understand the drivers of GAS transmission using mathematical models.
Research
Time to tackle rheumatic heart disease: Data needed to drive global policy dialoguesThis report provides an update on the contemporary global and regional policy landscapes relevant to rheumatic heart disease